CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

CymaBay Therapeutics, Inc.

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC).Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.

msh id	COM:CYMABAY
symbol	CBAY
name	CymaBay Therapeutics, Inc.
homepage url	https://www.cymabay.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	101
crunchbase url	-
linkedin url	-
founders	-

market cap	3.73B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	59.1
growth score 28	15.1
growth score 90	14.38
growth score 365	93.5

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.43
growth cost of revenue	-0.04
growth depreciation and amortization	-0.66
growth ebitda	-0.11
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	1.07
growth gross profit	43.81
growth gross profit ratio	-

COM:CYMABAY

CymaBay Therapeutics Inc

Last Close

32.47

21/03 20:00

Market Cap

3.73B

Beta: -

Volume Today

8.35M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	132.75M
cost of revenue	132.75M
depreciation and amortization	681K
ebitda	-101M
ebitda ratio	-3.25
eps	-0.99
eps diluted	-0.99
operating expenses	132.07M
operating income	-101.68M
operating income ratio	-3.27

accounts receivables	-
capital expenditure	-445K
cash at beginning of period	20.29M
cash at end of period	206.54M
inventory	-
working capital ttm	427.99M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-